Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 29;23(23):14939.
doi: 10.3390/ijms232314939.

Towards the Search for Potential Biomarkers in Osteosarcoma: State-of-the-Art and Translational Expectations

Leonel Pekarek  1   2   3 , Basilio De la Torre-Escuredo  2   4   5 , Oscar Fraile-Martinez  1   2 , Cielo García-Montero  1   2 , Miguel A Saez  1   2   6 , David Cobo-Prieto  7 , Luis G Guijarro  2   8 , Jose V Saz  9 , Patricia De Castro-Martinez  1 , Diego Torres-Carranza  1 , Tatiana Pekarek  1 , Ana Clara Carrera  10 , Melchor Alvarez-Mon  1   2   11 , Miguel A Ortega  1   2   12
Affiliations
Review

Towards the Search for Potential Biomarkers in Osteosarcoma: State-of-the-Art and Translational Expectations

Leonel Pekarek et al. Int J Mol Sci. .

Abstract

Osteosarcoma represents a rare cause of cancer in the general population, accounting for <1% of malignant neoplasms globally. Nonetheless, it represents the main cause of malignant bone neoplasm in children, adolescents and young adults under 20 years of age. It also presents another peak of incidence in people over 50 years of age and is associated with rheumatic diseases. Numerous environmental risk factors, such as bone diseases, genetics and a history of previous neoplasms, have been widely described in the literature, which allows monitoring a certain group of patients. Diagnosis requires numerous imaging tests that make it possible to stratify both the local involvement of the disease and its distant spread, which ominously determines the prognosis. Thanks to various clinical trials, the usefulness of different chemotherapy regimens, radiotherapy and surgical techniques with radical intent has now been demonstrated; these represent improvements in both prognosis and therapeutic approaches. Osteosarcoma patients should be evaluated in reference centres by multidisciplinary committees with extensive experience in proper management. Although numerous genetic and rheumatological diseases and risk factors have been described, the use of serological, genetic or other biomarkers has been limited in clinical practice compared to other neoplasms. This limits both the initial follow-up of these patients and screening in populations at risk. In addition, we cannot forget that the diagnosis is mainly based on the direct biopsy of the lesion and imaging tests, which illustrates the need to study new diagnostic alternatives. Therefore, the purpose of this study is to review the natural history of the disease and describe the main biomarkers, explaining their clinical uses, prognosis and limitations.

Keywords: circulating tumour cells; genetic markers; immunohistochemical markers; microRNA; osteosarcoma; serological markers.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
A global perspective on the available biomarkers studied in osteosarcoma.
Figure 2
Figure 2
An overview of the clinical diagnosis of osteosarcoma.
See this image and copyright information in PMC

References

    1. Burningham Z., Hashibe M., Spector L., Schiffman J.D. The Epidemiology of Sarcoma. Clin. Sarcoma Res. 2012;2:14. doi: 10.1186/2045-3329-2-14. - DOI - PMC - PubMed
    1. Hui J.Y.C. Epidemiology and Etiology of Sarcomas. Surg. Clin. N. Am. 2016;96:901–914. doi: 10.1016/j.suc.2016.05.005. - DOI - PubMed
    1. SEOM Las Cifras del Cancer en España 2021. 2021. [(accessed on 22 October 2022)]. Available online: https://seom.org/images/Cifras_del_cancer_en_Espnaha_2021.pdf.
    1. Ottaviani G., Jaffe N. Cancer Treatment and Research. Springer; Boston, MA, USA: 2009. The Epidemiology of Osteosarcoma; pp. 3–13. - DOI - PubMed
    1. Le Vu B., de Vathaire F., Shamsaldin A., Hawkins M.M., Grimaud E., Hardiman C., Diallo I., Vassal G., Bessa E., Campbell S., et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int. J. Cancer. 1998;77:370–377. doi: 10.1002/(SICI)1097-0215(19980729)77:3<370::AID-IJC11>3.0.CO;2-C. - DOI - PubMed